The Taskforce is calling for Expressions of Interest from suitably qualified individuals with paediatric or clinical engineering expertise to join the newly established Infection Prevention and Control (IPC) Panel, a collaboration between the Taskforce and the Infection Control Expert Group (ICEG).
Please note, applications for other sub-specialty positions have closed.
Please click here to view the Expression of Interest, which outlines the role of IPC Panel members, key selection criteria and the application process.
Expressions of interest close Thursday 19 November 2020.
Deputy Chair of the Taskforce Guidelines Leadership Group and Methods Chair of the Pregnancy and Postpartum Care Panel, A/Prof Joshua Vogel was this week awarded the 2020 Nature Research Award for Driving Global Impact (DGI) for his outstanding body of work in maternal and child health, including research focused on the prevention of newborn deaths due to premature births in low and middle-income countries. Read more here.
Joshua also led the recent publication of a Taskforce paper on the Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID‐19 Clinical Evidence Taskforce in the Australian and New Zealand Journal of Obstetrics and Gynaecology (ANZJOG). Read here.
The Taskforce is interested in understanding how our guidance is being used. Dr Tari Turner has been conducting interviews with clinicians across all disciplines and is now seeking particular feedback from infectious diseases physicians and critical care and/or emergency practitioners.
If you have recommendations of good examples of the use of our guidance, or people we should talk to about how our guidance is being used, please email [email protected]
Updated wording to reflect that the strong recommendation against remdesivir for adults hospitalised with COVID-19 who require ventilation relates to the commencement of treatment in this patient group:
Do not start remdesivir in adults hospitalised with COVID-19 who require ventilation.
Remdesivir should be continued with the appropriate dose and duration, if it was started prior to requiring ventilation. Within this population, ventilation includes invasive or non-invasive mechanical ventilation and extracorporeal membrane oxygenation (ECMO).Use of remdesivir may still be considered in the context of randomised trials with appropriate ethical approval, such as combination therapies that include remdesivir.
Text has been added to each section in our online guideline platform MAGICApp to indicate which panel is the primary panel for the development of the recommendations within that section.
The Taskforce is continually monitoring research to update recommendations weekly as new evidence accumulates.
We are currently reviewing evidence to develop recommendations and flowcharts to guide practice in areas including:
Cochrane has published a new review this week: Interventions to support the resilience and mental health of frontline health and social care professionals during and after a disease outbreak, epidemic or pandemic: a mixed methods systematic review. Read here.
The full list of Cochrane Reviews and related content from the Cochrane Library can be found here.
The ANZ Guidelines International Network are hosting a webinar to discuss the collaboration to support healthcare for First Nations people during the COVID-19 pandemic.
Topic:First nations-led guideline development – supporting prevention and management COVID-19 in primary healthcare
Date:Friday, 27 November 2020
Time: 11am-12pm AEDT
Speakers: A/Prof Catherine Chamberlain, NHMRC Career fellow, Editor of NHMRC’s Guidelines for Guidelines module: Engaging Aboriginal and Torres Strait Islander people in guideline development; Dr Jason Agostino, Medical advisor to NACCHO; Professor Peter O’Mara, Chair, RACGP Aboriginal and Torres Strait Islander Health.
It is a core mission of the Taskforce to engage with frontline clinicians to rapidly identify and address priority clinical questions.
Each week we collect suggestions for new clinical questions or topics for consideration by the Taskforce. A document that lists all of the suggested questions, topics and new patient groups that we have received to date is available here.
Please encourage your clinical colleagues to provide their insights via the website.